Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 5 | 6 |
1.1 List of Tables | 7 | 1 |
1.2 List of Figures | 8 | 3 |
2 Introduction | 11 | 19 |
2.1 Therapy Area Introduction | 11 | 1 |
2.2 Epidemiology | 11 | 1 |
2.2.1 Leukemia | 12 | 1 |
2.2.2 Lymphoma | 13 | 1 |
2.2.3 Myeloma | 14 | 1 |
2.3 Pathophysiology | 15 | 1 |
2.3.1 Leukemia | 15 | 1 |
2.3.2 Lymphoma | 16 | 2 |
2.3.3 Myeloma | 18 | 2 |
2.4 Symptoms | 20 | 1 |
2.5 Diagnosis | 20 | 1 |
2.5.1 Leukemia | 20 | 1 |
2.5.1.1 Blood Tests and Immunophenotyping | 20 | 1 |
2.5.1.2 Flow-Cytometry | 20 | 1 |
2.5.1.3 Cytogenetic Analysis | 20 | 1 |
2.5.1.4 Molecular Diagnostics | 21 | 1 |
2.5.2 Lymphoma | 21 | 1 |
2.5.2.1 Biopsy | 21 | 1 |
2.5.2.2 Flow-Cytometry and Immunophenotyping | 21 | 1 |
2.5.3 Myeloma | 21 | 1 |
2.6 Prognosis and Survival | 22 | 3 |
2.6.1 Survival | 25 | 1 |
2.7 Treatment | 25 | 1 |
2.7.1 Surgery and Radiation Therapy | 26 | 1 |
2.7.2 Stem Cell Transplantation | 27 | 1 |
2.7.3 Pharmacological Therapies | 27 | 1 |
2.7.3.1 Chemotherapy | 27 | 1 |
2.7.3.2 Targeted Therapy | 28 | 2 |
3 Key Marketed Products | 30 | 19 |
3.1 Overview | 30 | 1 |
3.2 Rituxan/Mabthera (rituximab) Roche | 31 | 2 |
3.3 Gleevec/Glivec (Imatinib) Novartis | 33 | 2 |
3.4 Revlimid (lenalidomide) Celgene | 35 | 2 |
3.5 Velcade (bortezomib) Millennium/Takeda/Johnson &Johnson | 37 | 1 |
3.6 Sprycel (dasatinib) Bristol-Myers Squibb/Otsuka Pharmaceutical | 38 | 1 |
3.7 Tasigna (nilotinib) Novartis | 39 | 2 |
3.8 Pomalyst (pomalidomide) Celgene | 41 | 1 |
3.9 Vidaza (azacitidine) Celgene | 42 | 1 |
3.10 Kyprolis (carfilzomib) Onyx/Amgen | 43 | 2 |
3.11 Adcetris (brentuximab vedotin) Seattle Genetics/Millennium | 45 | 1 |
3.12 Imbruvica (ibrutinib) AbbVie/Johnson &Johnson | 46 | 2 |
3.13 Conclusion | 48 | 1 |
4 Pipeline Landscape Assessment | 49 | 23 |
4.1 Overview | 49 | 1 |
4.2 Pipeline Development Landscape | 49 | 3 |
4.3 Molecular Targets in the Pipeline | 52 | 2 |
4.4 Clinical Trials | 54 | 1 |
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target | 54 | 1 |
4.4.1.1 Indication | 55 | 1 |
4.4.1.2 Molecule Type | 56 | 1 |
4.4.1.3 Molecular Target | 57 | 1 |
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target | 58 | 1 |
4.4.2.1 Indication | 59 | 1 |
4.4.2.2 Molecule Type | 60 | 1 |
4.4.2.3 Molecular Target | 60 | 1 |
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target | 61 | 1 |
4.4.3.1 Indication | 62 | 1 |
4.4.3.2 Molecule Type | 63 | 1 |
4.4.3.3 Molecular Target | 63 | 1 |
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target | 64 | 1 |
4.4.4.1 Indication | 65 | 1 |
4.4.4.2 Molecule Type | 66 | 1 |
4.4.4.3 Molecular Target | 66 | 1 |
4.4.5 Conclusion | 67 | 1 |
4.5 Multi-scenario Market Forecast to 2023 | 68 | 1 |
4.5.1 Overall Market Size | 68 | 2 |
4.6 Generic Penetration | 70 | 2 |
5 Revenue Forecast by Molecular Target | 72 | 18 |
5.1 Cancer Immunotherapies/Tumor-Associated Antigen | 72 | 1 |
5.2 Signal Transduction | 73 | 1 |
5.3 Receptor Tyrosine Kinases and Ligands | 73 | 1 |
5.4 Revenue and Market Share Analysis by Company | 74 | 4 |
5.4.1 Celgene Will Revenue Loss Associated with Vidaza, Thalomid and Istodax Impact Celgene s Position as Market Leader? | 78 | 1 |
5.4.2 Roche Will the Patent Expiry of Rituxan Significantly Diminish Revenues? | 79 | 1 |
5.4.3 AbbVie/Pharmacyclics AbbVie Acquiring Pharmacyclics will Drive AbbVie s Sales Growth | 80 | 1 |
5.4.4 Novartis Large and Growing Product Portfolio to Maintain Revenue Growth | 81 | 1 |
5.4.5 Johnson &Johnson Imbruvica and Velcade Partnerships to be Predominant Contributors to Revenue Growth | 82 | 1 |
5.5 Assessment of Key Pipeline Products | 83 | 1 |
5.5.1 Venetoclax (ABT-199) AbbVie/Roche | 83 | 1 |
5.5.1.1 Drug Forecast | 84 | 1 |
5.5.2 KTE-C19 Kite Pharma | 84 | 1 |
5.5.2.1 Drug Forecast | 84 | 1 |
5.5.3 Selinexor (KPT-330) Karyopharm Therapeutics | 85 | 1 |
5.5.3.1 Drug Forecast | 85 | 1 |
5.5.4 Polatuzumab Vedotin (RG-7596) Roche | 86 | 1 |
5.5.4.1 Drug Forecast | 86 | 1 |
5.5.5 Tisagenlecleucel-T (CTL-019) Novartis | 87 | 1 |
5.5.5.1 Drug Forecast | 87 | 1 |
5.5.6 Midostaurin (PKC-412) Novartis | 88 | 1 |
5.5.6.1 Drug Forecast | 88 | 1 |
5.5.7 Conclusion | 89 | 1 |
6 Company Analysis and Positioning | 90 | 6 |
6.1 Company Landscape | 91 | 1 |
6.2 Marketed and Pipeline Portfolio Analysis | 92 | 4 |
7 Strategic Consolidations | 96 | 14 |
7.1 Licensing Deals | 96 | 1 |
7.1.1 Deal by Region, Year and Value | 96 | 2 |
7.1.2 Deals by Stage of Development and Value | 98 | 1 |
7.1.3 Deals by Molecule Type, Molecular Target and Value | 99 | 2 |
7.1.4 Table for Licensing Deals Valued Above $100m | 101 | 2 |
7.2 Co-development Deals | 103 | 1 |
7.2.1 Deals by Region, Year and Value | 103 | 2 |
7.2.2 Deals by Stage of Development and Value | 105 | 1 |
7.2.3 Deals by Molecule Type, Mechanism of Action and Value | 106 | 2 |
7.2.4 Table for Co-development Deals Valued Above $100m | 108 | 2 |
8 Appendix | 110 | 38 |
8.1 Bibliography | 110 | 5 |
8.2 Table of All Clinical Stage Pipeline Products | 115 | 28 |
8.3 Abbreviations | 143 | 2 |
8.4 Disease List | 145 | 1 |
8.5 Methodology | 145 | 2 |
8.5.1 Secondary Research | 145 | 1 |
8.5.2 Market Size and Revenue Forecasts | 146 | 1 |
8.5.3 Pipeline Analysis | 146 | 1 |
8.5.4 Competitive Landscape | 146 | 1 |
8.6 Contact Us | 147 | 1 |
8.7 Disclaimer | 147 | 1 |